Cha Len Lee

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 3

Top Topics

Peritoneal Dialysis

Squamous Cell Carcinoma

End Stage Renal Disease

Top Venues

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Cha Len Lee, Mark Freeman, Kelly W Burak, Gordon T Moffat, Conor D J O'Donnell, Philip Q Ding, Hanna Lyubetska, Brandon M Meyers, Vallerie Gordon, Ekaterina Kosyachkova, Roxana Bucur, Winson Y Cheung, Jennifer J Knox, Vincent C Tam
Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications. Cancers 16 (16) (2024)
Cha Len Lee, Mark Freeman, Kelly W Burak, Gordon T Moffat, Conor D J O'Donnell, Philip Q Ding, Hanna Lyubetska, Brandon M Meyers, Vallerie Gordon, Ekaterina Kosyachkova, Roxana Bucur, Winson Y Cheung, Jennifer J Knox, Vincent C Tam
Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications. Cancers 16 (16) (2024)
Cha Len Lee, Grainne M O'Kane, Warren P Mason, Wen-Jiang Zhang, Pavlina Spiliopoulou, Aaron Richard Hansen, Robert C Grant, Jennifer J Knox, Tracy L Stockley, Gelareh Zadeh, Eric X Chen
Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular cancer therapeutics (2023)